Table-III.
Etiologic differences between three groups.
| Etiology | All hepatotoxicity attacks(156) | Group1(83) | Group 2(34) | Group 3 (36) | p value |
|---|---|---|---|---|---|
| Drugs, n(%)* | 68 (43.6) | 27 (32.1) | 18 (51.4) | 23 (62.2) | 0.005 |
| MMF, n(%) | 26 (16.6) | 9 (10.8) | 6 (17.6) | 11 (30.5) | 0.035 |
| Tac, n(%) | 13 (8.3) | 5 (6) | 4 (11.4) | 4 (10.8) | - |
| CyA, n(%) | 4 (2.6) | 2 (2.4) | 0 (0) | 2 (5.4) | - |
| EVL, n(%) | 1 (0.6) | 0 (0) | 1 (2.9) | 0 (0) | - |
| Sirolimus, n(%) | 1 (0.6) | 0 (0) | 0 (0) | 1 (2.7) | - |
| Antibiotics, n(%) | 26 (16.6) | 12 (14.3) | 7 (20) | 7 (18.9) | NS |
| TMP/SMX, n(%)** | 10 (6.4) | 5 (6) | 2 (5.7) | 3 (8.1) | - |
| Unknown etiology, n(%)*** | 63 (40.4) | 43 (51.2) | 15 (42.9) | 5 (13.5) | <0.001 |
| Sepsis/hypoxy, n(%) | 8 (5.1) | 4 (4.8) | 2 (5.7) | 2 (5.4) | NS |
| CMV, n(%) | 8 (5.1) | 2 (2.4) | 0 (0) | 6 (16.2) | - |
| Hyperlipidemia, n(%) | 4 (2.6) | 4 (4.8) | 0 (0) | 0 (0) | - |
| Hepatitis B, n(%) | 2 (1.3) | 2 (2.4) | 0 (0) | 0 (0) | - |
| Acute pancreatitis, n(%) | 1 (0.6) | 1 (1.2) | 0 (0) | 0 (0) | - |
| Cholelithiasis, n(%) | 1 (0.6) | 0 (0) | 0 (0) | 1 (2.7) | - |
| Drug + CMV, n(%) | 1 (0.6) | 1 (1.2) | 0 (0) | 0 (0) | - |
Tac: Tacrolimus, MMF: Mycophenolat mophetil, P: Prednisolone, CyA: Cyclosporin A, EVL: Everolimus,
TMP/SMX: trimethoprim/sulfamethoxazole, CMV: Cytomegalovirus
*
Significant differences were available between group 1-2 and group1-3;
**
We evaluated the TMP/SMX as an antibiotic, and we made statistical analysis for TMP/SMX according to this.
***
Significant differences were available between group 1-3 and group 2-3. NS: Not significant.